Restricted accessLetterFirst published online 2024-9
Increased Risk of Keratinocyte Carcinomas,Merkel Cell Carcinoma,and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor,Ruxolitinib
BlechmanABCabellCEWeinbergerCH, et al. Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. J Drugs Dermatol. 2017;16(5):508-511.
2.
LeeGHGuzmanAKDivitoSJSoifferRJSilkAWSchmultsCD. cutaneous squamous-cell carcinoma after treatment with ruxolitinib or belumosudil. N Engl J Med. 2023;389(2):188-190. doi:10.1056/NEJMc2304157
3.
LinJQLiSQLiS, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86(2):339-344. doi:10.1016/j.jaad.2021.10.004
4.
RampotasACarter-BrzezinskiLSomervailleTCP, et al. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024;143(2):178-182. doi:10.1182/blood.2023022345
5.
RastrelliMFerrazziBTropeaS, et al. Aggressive Merkel cell carcinoma after Janus kinase inhibitor ruxolitinib for polycythemia vera. In Vivo. 2019;33(5):1667-1669. doi:10.21873/invivo.11653
